CN111936514A - 多价抗体 - Google Patents

多价抗体 Download PDF

Info

Publication number
CN111936514A
CN111936514A CN201980023259.9A CN201980023259A CN111936514A CN 111936514 A CN111936514 A CN 111936514A CN 201980023259 A CN201980023259 A CN 201980023259A CN 111936514 A CN111936514 A CN 111936514A
Authority
CN
China
Prior art keywords
binding domain
antibody
domain
multivalent antibody
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980023259.9A
Other languages
English (en)
Chinese (zh)
Inventor
科内利斯·阿德里安·德克吕夫
林达·约翰娜·阿莱达·亨德里克斯
敦·洛格滕伯格
彼得·福科·万隆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merus BV
Original Assignee
Merus BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus BV filed Critical Merus BV
Publication of CN111936514A publication Critical patent/CN111936514A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980023259.9A 2018-03-30 2019-03-29 多价抗体 Pending CN111936514A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650467P 2018-03-30 2018-03-30
US62/650,467 2018-03-30
PCT/NL2019/050199 WO2019190327A2 (en) 2018-03-30 2019-03-29 Multivalent antibody

Publications (1)

Publication Number Publication Date
CN111936514A true CN111936514A (zh) 2020-11-13

Family

ID=66349617

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980023259.9A Pending CN111936514A (zh) 2018-03-30 2019-03-29 多价抗体

Country Status (18)

Country Link
US (3) US11952424B2 (https=)
EP (1) EP3774885A2 (https=)
JP (2) JP7603578B2 (https=)
KR (1) KR20200139189A (https=)
CN (1) CN111936514A (https=)
AR (1) AR115320A1 (https=)
AU (2) AU2019243665B2 (https=)
BR (1) BR112020019795A2 (https=)
CA (1) CA3094318A1 (https=)
EA (1) EA202091871A1 (https=)
IL (1) IL277672A (https=)
MA (1) MA52212A (https=)
MX (1) MX2020010267A (https=)
NZ (1) NZ767923A (https=)
PH (1) PH12020551504A1 (https=)
SG (1) SG11202009036YA (https=)
TW (1) TW202003569A (https=)
WO (1) WO2019190327A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114349865A (zh) * 2020-04-29 2022-04-15 丹生医药技术(上海)有限公司 一种pd-1/lag-3四价双特异性抗体、其制备方法和用途
CN114605546A (zh) * 2019-03-29 2022-06-10 美勒斯公司 Cd3结合分子
CN117986350A (zh) * 2023-02-23 2024-05-07 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010267A (es) 2018-03-30 2020-11-06 Merus Nv Anticuerpo multivalente.
CN113227132A (zh) 2018-12-31 2021-08-06 美勒斯公司 混合的结合域
US20220380440A1 (en) 2018-12-31 2022-12-01 Merus N.V. Truncated multivalent multimers
TW202546002A (zh) 2019-03-29 2025-12-01 荷蘭商美勒斯公司 Cd3結合分子
US20210054049A1 (en) 2019-05-09 2021-02-25 Merus N.V. Variant domains for multimerizing proteins and separation thereof
CN116199780A (zh) 2019-12-24 2023-06-02 美勒斯公司 TGF-β-RII结合蛋白质
CN116407626A (zh) * 2020-01-29 2023-07-11 美勒斯公司 用于调节免疫细胞衔接效应的手段和方法
JP7784039B2 (ja) * 2020-03-31 2025-12-11 公立大学法人大阪 多重特異性抗体及びその製造方法
EP4149627A4 (en) * 2020-05-14 2024-05-29 The General Hospital Corporation POLYPEPTIDE AGONISTS OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY
WO2021226984A1 (zh) 2020-05-15 2021-11-18 三生国健药业（上海）股份有限公司 一种抗pd-1和pd-l1的四价双特异性抗体
MX2022014208A (es) 2020-05-21 2022-12-07 Merus Nv Metodos y medios para la produccion de moleculas tipo ig.
CA3196729A1 (en) * 2020-11-11 2022-05-19 Tural AKSEL Affinity reagents having enhanced binding and detection characteristics
CN115536749A (zh) * 2021-06-29 2022-12-30 三生国健药业（上海）股份有限公司 三特异性抗体、其制备方法和用途
CN119110809A (zh) 2022-02-23 2024-12-10 Xencor股份有限公司 抗CD28 x抗PSMA抗体
US20240117030A1 (en) * 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
JP2025512391A (ja) * 2022-04-13 2025-04-17 ゼンコア インコーポレイテッド Ｐｄ－ｌ１、ｐｄ－ｌ２及び／またはｃｄ２８と結合する抗体
TW202432587A (zh) 2022-12-27 2024-08-16 荷蘭商美勒斯公司 產生雙特異性蛋白之方法
EP4642800A1 (en) * 2022-12-30 2025-11-05 Merus N.V. Promiscuous cd3 binding molecules
US20240327515A1 (en) * 2023-03-31 2024-10-03 Ibio, Inc. Anti-cd3 antibodies
WO2025221674A1 (en) * 2024-04-15 2025-10-23 Eli Lilly And Company Baffr x cd3 bispecific antibodies and methods of use
WO2025230409A1 (en) 2024-04-30 2025-11-06 Merus N.V. Multispecific antibody-drug conjugates
WO2025230410A1 (en) 2024-04-30 2025-11-06 Merus N.V. Multispecific antibody-drug conjugates
WO2026013015A1 (en) * 2024-07-09 2026-01-15 Merus N.V. Multispecific binding moieties comprising calr and cd3 binding domains
WO2026018064A1 (en) 2024-07-16 2026-01-22 Merus N.V. Multispecific multi-drug antibody-drug conjugates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077342A1 (en) * 2000-04-11 2001-10-18 Genentech, Inc. Multivalent antibodies and uses therefor
WO2013157953A1 (en) * 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
CN103857700A (zh) * 2011-08-26 2014-06-11 梅里麦克制药股份有限公司 串联fc双特异性抗体

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
JP2004523205A (ja) * 2000-07-25 2004-08-05 イムノメディクス， インコーポレイテッド 多価標的結合タンパク質
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PL3456190T3 (pl) 2008-06-27 2022-06-06 Merus N.V. Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
CA2762837C (en) 2009-05-20 2021-08-03 Novimmune S.A. Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
TW201100543A (en) * 2009-05-27 2011-01-01 Hoffmann La Roche Tri-or tetraspecific antibodies
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
ES2542744T3 (es) 2009-12-17 2015-08-11 Novimmune Sa Bibliotecas de polipéptidos sintéticos y métodos para generar variantes polipeptídicas diversificadas de forma natural
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
HK1204557A1 (en) 2012-05-31 2015-11-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-l1
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
EP3470431A1 (en) * 2012-09-27 2019-04-17 Merus N.V. Bispecific igg antibodies as t cell engagers
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
CA2896359A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
BR112016015140A2 (pt) * 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
IL301147A (en) 2014-02-28 2023-05-01 Merus Nv An antibody that binds to ErbB-2 and ErbB-3
EP3786186A1 (en) 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
EP3204416A1 (en) 2014-10-09 2017-08-16 EngMab AG Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
WO2016105450A2 (en) * 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
SI3115376T1 (sl) * 2015-07-10 2018-12-31 Merus N.V. Humana protitelesa, ki vežejo CD3
US10683369B2 (en) 2015-08-03 2020-06-16 Engmab Sàrl Monoclonal antibodies against BCMA
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
CA3002957A1 (en) * 2015-10-23 2017-04-27 Koninklijke Nederlandse Akademie Van Wetenschappen Binding molecules that inhibit cancer growth
CN109476741B (zh) 2016-03-25 2023-02-24 拜奥穆尼克斯制药 与cd38和pd-l1结合的分子
JP2019516362A (ja) * 2016-04-27 2019-06-20 ファイザー・インク 抗ｉｌ−３３抗体、その組成物、方法および使用
CN109563166B (zh) 2016-04-28 2022-12-20 拜奥穆尼克斯制药 靶向egfr和her2的双特异性抗体
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
BR112019005895A2 (pt) * 2016-09-23 2019-06-11 Merus N.V. moléculas de ligação que modulam uma atividade biológica expressa por uma célula
KR20240000650A (ko) 2016-10-19 2024-01-02 인벤라 인코포레이티드 항체 구조물
EP4295918A3 (en) 2016-11-02 2024-03-20 Bristol-Myers Squibb Company Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
US20200291130A1 (en) * 2017-03-31 2020-09-17 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
AU2018246873B2 (en) * 2017-03-31 2021-05-06 Merus B.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
EA202090005A1 (ru) * 2017-07-06 2020-06-18 Мерус Н.В. Антитела, модулирующие биологическую активность, проявляемую клеткой
EA202090003A1 (ru) * 2017-07-06 2020-06-18 Мерус Н.В. Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка
EP3649155A1 (en) * 2017-07-06 2020-05-13 Merus N.V. Bispecific anti pd1-anti tim3 antibodies
CN118580366A (zh) * 2017-08-09 2024-09-03 美勒斯公司 结合EGFR和cMET的抗体
CN111432838A (zh) * 2017-12-01 2020-07-17 美勒斯公司 使用双特异性抗体和il-15进行联合治疗
MX2020010267A (es) 2018-03-30 2020-11-06 Merus Nv Anticuerpo multivalente.
CN113227132A (zh) * 2018-12-31 2021-08-06 美勒斯公司 混合的结合域
US20210054049A1 (en) * 2019-05-09 2021-02-25 Merus N.V. Variant domains for multimerizing proteins and separation thereof
PH12022551291A1 (en) * 2019-11-26 2023-11-20 Novartis Ag Chimeric antigen receptors binding bcma and cd19 and uses thereof
CN116407626A (zh) * 2020-01-29 2023-07-11 美勒斯公司 用于调节免疫细胞衔接效应的手段和方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077342A1 (en) * 2000-04-11 2001-10-18 Genentech, Inc. Multivalent antibodies and uses therefor
CN103857700A (zh) * 2011-08-26 2014-06-11 梅里麦克制药股份有限公司 串联fc双特异性抗体
WO2013157953A1 (en) * 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAMILLA DE NARDIS等: "A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1", J. BIOL. CHEM., vol. 292, no. 35, 27 June 2017 (2017-06-27) *
ROLAND E. KONTERMANN: "Dual targeting strategies with bispecific antibodies", MABS, vol. 4, no. 2, 1 March 2012 (2012-03-01), pages 2, XP055566203, DOI: 10.4161/mabs.4.2.19000 *
韩明勇等主编: "肿瘤分子靶向治疗学", vol. 1, 31 August 2008, 济南出版社, pages: 118 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114605546A (zh) * 2019-03-29 2022-06-10 美勒斯公司 Cd3结合分子
CN114349865A (zh) * 2020-04-29 2022-04-15 丹生医药技术(上海)有限公司 一种pd-1/lag-3四价双特异性抗体、其制备方法和用途
CN114349865B (zh) * 2020-04-29 2023-06-09 三生国健药业（上海）股份有限公司 一种pd-1/lag-3四价双特异性抗体、其制备方法和用途
CN117986350A (zh) * 2023-02-23 2024-05-07 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用

Also Published As

Publication number Publication date
JP2021519610A (ja) 2021-08-12
WO2019190327A8 (en) 2021-06-17
EA202091871A1 (ru) 2021-06-22
MX2020010267A (es) 2020-11-06
US20190352401A1 (en) 2019-11-21
AR115320A1 (es) 2020-12-23
IL277672A (en) 2020-11-30
JP7603578B2 (ja) 2024-12-20
AU2019243665A1 (en) 2020-10-08
JP2024161509A (ja) 2024-11-19
US20240352127A1 (en) 2024-10-24
AU2019243665B2 (en) 2023-06-01
NZ767923A (en) 2024-11-29
TW202003569A (zh) 2020-01-16
SG11202009036YA (en) 2020-10-29
MA52212A (fr) 2021-02-17
WO2019190327A3 (en) 2019-11-14
AU2023222983A1 (en) 2023-09-21
BR112020019795A2 (pt) 2021-01-05
EP3774885A2 (en) 2021-02-17
KR20200139189A (ko) 2020-12-11
US20240360217A1 (en) 2024-10-31
PH12020551504A1 (en) 2021-09-13
WO2019190327A2 (en) 2019-10-03
CA3094318A1 (en) 2019-10-03
US11952424B2 (en) 2024-04-09

Similar Documents

Publication Publication Date Title
US20240360217A1 (en) Multivalent antibody
JP2023061969A (ja) Ｓｉｒｐ－アルファドメインまたはそのバリアントを有する構築物
KR20220071263A (ko) Cd3을 표적으로 하는 항체, 이중 특이성 항체 및 이의 용도
HK1217958A1 (zh) 四价双特异性抗体
WO2021170082A1 (zh) 抗cd47/抗pd-l1抗体及其应用
WO2014014796A1 (en) Multi-specific igg-(fab)2 constructs containing t-cell receptor constant domains
US20250236682A1 (en) Antigen-binding protein comprising two fc domains and use thereof
TW202346337A (zh) Ilt3及cd3結合劑以及其使用方法
JP2025542327A (ja) 新規抗ｇｐｒｃ５ｄ抗体
JP7837331B2 (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
JP7440516B2 (ja) 切断多価多量体
JP2022550976A (ja) ハイブリッド抗体
US20250312452A1 (en) Antibody targeting claudin18.2 and its applications
US20250075002A1 (en) MUC1 and CD16A Antibodies and Methods of Use
JP2025528101A (ja) 多重特異性ポリペプチド複合体
JP2025542322A (ja) Ｇｐｒｃ５ｄを標的とする多重特異性ポリペプチド複合物
KR20260016889A (ko) B7-h3을 표적하는 항체, 및 이를 포함하는 키메라 항원 수용체
JP2026513915A (ja) ヒンジが修飾された二重特異性抗体
WO2024094159A1 (zh) 靶向人源ror1的单域抗体
TW202214705A (zh) 抗tigit抗體及雙抗體和它們的應用
HK40096583A (zh) 能够结合ror2的抗体以及结合ror2和cd3的双特异性抗体
CN116685606A (zh) 选择性地与cldn6和cd3结合的多肽构建体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination